NCT01308060View on ClinicalTrials.gov

A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)

PHASE3CompletedINTERVENTIONAL
Enrollment

335

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Canthal Lines
Interventions
DRUG

Botulinum Toxin Type A

During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.

OTHER

Placebo

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY